Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1988 1
1990 1
1991 1
1994 4
1995 2
1996 6
1998 3
2000 3
2001 5
2002 2
2003 5
2004 3
2005 1
2006 2
2007 5
2008 5
2009 5
2010 5
2011 4
2012 2
2013 8
2014 5
2015 8
2016 5
2017 3
2018 3
2019 4
2020 1
2021 1
2022 2
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Unresectable Clear Cell Renal Cell Carcinoma"
Page 1
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. Balar AV, et al. Lancet Oncol. 2017 Nov;18(11):1483-1492. doi: 10.1016/S1470-2045(17)30616-2. Epub 2017 Sep 26. Lancet Oncol. 2017. PMID: 28967485 Clinical Trial.
BACKGROUND: More than half of all patients with advanced urothelial cancer cannot receive standard, first-line cisplatin-based chemotherapy because of renal dysfunction, poor performance status, or other comorbidities. ...INTERPRETATION: First-line pembrolizumab has antitu …
BACKGROUND: More than half of all patients with advanced urothelial cancer cannot receive standard, first-line cisplatin-based chemotherapy …
Acrometastases.
Mavrogenis AF, Mimidis G, Kokkalis ZT, Karampi ES, Karampela I, Papagelopoulos PJ, Armaganidis A. Mavrogenis AF, et al. Eur J Orthop Surg Traumatol. 2014 Apr;24(3):279-83. doi: 10.1007/s00590-013-1311-1. Epub 2013 Sep 8. Eur J Orthop Surg Traumatol. 2014. PMID: 24013815 Review.
The prognosis of the patients with acrometastatic cancer is poor; the mean survival time after diagnosis is <6 months. An exception seems to be the patients with renal cell carcinoma, if treated with radical surgical resection, and a long latency pe …
The prognosis of the patients with acrometastatic cancer is poor; the mean survival time after diagnosis is <6 months. An exceptio …
Treatment of advanced pediatric renal cell carcinoma.
Ambalavanan M, Geller JI. Ambalavanan M, et al. Pediatr Blood Cancer. 2019 Aug;66(8):e27766. doi: 10.1002/pbc.27766. Epub 2019 Apr 23. Pediatr Blood Cancer. 2019. PMID: 31012542
BACKGROUND: Pediatric renal cell carcinoma (pRCC) is the second most common renal malignancy of childhood; however, treatment data for advanced disease is lacking. ...Translocation morphology RCC (tRCC) was the most common subtype (16; 64%), followed b …
BACKGROUND: Pediatric renal cell carcinoma (pRCC) is the second most common renal malignancy of childhood; howev …
Treatment strategies for advanced renal cell carcinoma: A new paradigm for surgical treatment.
Tomita Y. Tomita Y. Int J Urol. 2016 Jan;23(1):13-21. doi: 10.1111/iju.12899. Epub 2015 Sep 7. Int J Urol. 2016. PMID: 26347163 Review.
The induction of targeted drugs for the treatment of metastatic renal cell carcinoma has changed the treatment strategy for systemic therapy. Surgical treatment for metastatic renal cell carcinoma should also be reconsidered in the light …
The induction of targeted drugs for the treatment of metastatic renal cell carcinoma has changed the treatment strategy …
Non-melanoma and non-renal cell carcinoma malignancies treated with interleukin-2.
Krastev Z, Koltchakov V, Tomov B, Koten JW. Krastev Z, et al. Hepatogastroenterology. 2003 Jul-Aug;50(52):1006-16. Hepatogastroenterology. 2003. PMID: 12845968 Review.
In unresectable pancreatic head carcinoma a total response was 85% with twice prolonged survival. ...In breast cancer interleukin-2 induced immunologically functional graft. Metastatic pulmonary carcinoma has a favorable prognosis concerning response a …
In unresectable pancreatic head carcinoma a total response was 85% with twice prolonged survival. ...In breast cancer interleu …
Overexpression of kif11 is a poor prognostic factor in clear cell renal cell carcinoma.
Kowalewski A, Jaworski D, Antosik P, Smolińska M, Ligmanowska J, Grzanka D, Szylberg Ł. Kowalewski A, et al. Pol J Pathol. 2022;73(2):82-87. doi: 10.5114/pjp.2022.118137. Pol J Pathol. 2022. PMID: 35979754 Free article.
INTRODUCTION: Unresectable renal cell carcinoma continues to be a great challenge due to our limited understanding of its underlying pathophysiology. We explored the relationship between KIF11 protein expression and the clinical courses of cl …
INTRODUCTION: Unresectable renal cell carcinoma continues to be a great challenge due to our limited understandi …
Renal cell carcinoma: current status and future directions.
Martel CL, Lara PN. Martel CL, et al. Crit Rev Oncol Hematol. 2003 Feb;45(2):177-90. doi: 10.1016/s1040-8428(02)00076-8. Crit Rev Oncol Hematol. 2003. PMID: 12604128 Review.
Although renal cell carcinoma accounts for only 3% of adult malignancies, it has been increasing in incidence by 2-4% per year since the 1970's. Cigarette smoking, obesity and end-stage renal disease are important risk factors. Genetic syndromes such a …
Although renal cell carcinoma accounts for only 3% of adult malignancies, it has been increasing in incidence by 2-4% p …
Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan.
Harada K, Nozawa M, Uemura M, Tatsugami K, Osawa T, Yamana K, Kimura G, Fujisawa M, Nonomura N, Eto M, Shinohara N, Tomita Y, Kondo Y, Ochi K, Anazawa Y, Uemura H. Harada K, et al. Int J Urol. 2019 Feb;26(2):202-210. doi: 10.1111/iju.13830. Epub 2018 Oct 21. Int J Urol. 2019. PMID: 30345560
OBJECTIVES: To clarify treatment patterns and outcomes for patients with unresectable or metastatic renal cell carcinoma in the molecular target therapy era in Japan. METHODS: A multicenter, retrospective medical chart review study was carried out. Pat …
OBJECTIVES: To clarify treatment patterns and outcomes for patients with unresectable or metastatic renal cell carci …
Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
Salem ME, Shah SN, Elson P, Garcia JA, Wood LS, Medsinge A, Campbell S, Dreicer R, Rini BI. Salem ME, et al. Clin Genitourin Cancer. 2014 Apr;12(2):117-23. doi: 10.1016/j.clgc.2013.08.001. Epub 2013 Oct 12. Clin Genitourin Cancer. 2014. PMID: 24126239
Neoadjuvant sunitinib might downsize unresectable renal cell carcinoma (RCC) and enable nephrectomy in a subset of patients. ...Neoadjuvant sunitinib might downsize unresectable tumors and enable nephrectomy. CT scans of unresectable prim …
Neoadjuvant sunitinib might downsize unresectable renal cell carcinoma (RCC) and enable nephrectomy in a subset …
Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer.
Reesink DJ, van Melick HHE, van der Nat PB, Los M, Horenblas S, van de Garde EMW; Santeon MIBC Study Group. Reesink DJ, et al. World J Urol. 2023 Jun;41(6):1551-1562. doi: 10.1007/s00345-023-04408-w. Epub 2023 May 5. World J Urol. 2023. PMID: 37145158
The purpose of this study was to evaluate the efficacy-effectiveness gap in palliative first-line (1L) chemotherapy treatment (CTx) for urothelial carcinoma of the bladder. METHODS: From seven Dutch teaching hospitals, all patients diagnosed with unresectable stage …
The purpose of this study was to evaluate the efficacy-effectiveness gap in palliative first-line (1L) chemotherapy treatment (CTx) for urot …
101 results